You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Arterial infusion chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)

Not yet recruiting
  • Recurrent Liver Cancer After Liver Transplantation
  • Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
  • (no location specified)
Apr 17, 2023

HepaSphere Transarterial Chemoembolization Combined With Hepatic

Not yet recruiting
  • Colorectal Liver Metastases (CRCLM)
  • DEB-TACE plus HAIC
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 25, 2023

HepaSphere Drug-eluting Bead Transarterial Chemoembolization

Recruiting
  • Advanced Hepatocellular Carcinoma (HCC)
  • DEB-TACE plus HAIC or HAIC alone
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 19, 2023

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Esophageal arterial infusion chemo, Systemic intravenous

Not yet recruiting
  • Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
  • Esophageal arterial infusion chemotherapy
  • Systemic intravenous chemotherapy
  • (no location specified)
May 15, 2022

Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer Trial in Beijing (Fruquintinib, Hepatic Arterial Infusion

Recruiting
  • Advanced Colorectal Carcinoma
  • Liver Metastasis Colon Cancer
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jun 1, 2022

Colorectal Liver Metastasis Trial in Shanghai (HAIC-FOLFOX combined with Sintilimab and Regorafenib)

Recruiting
  • Colorectal Liver Metastasis
  • HAIC-FOLFOX combined with Sintilimab and Regorafenib
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 1, 2023

Macrotrabecular Massive Hepatocellular Carcinoma Trial in Wuhan (HAIC, Camrelizumab plus Apatinib)

Recruiting
  • Macrotrabecular Massive Hepatocellular Carcinoma
  • HAIC
  • Camrelizumab plus Apatinib
  • Wuhan, Hubei, China
    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College,
May 1, 2023

Thrombocytopenia, Hepatocellular Carcinoma Trial in Guangzhou (Avatrombopag)

Not yet recruiting
  • Thrombocytopenia
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 17, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
May 24, 2023

Hepatocellular Carcinoma Trial in Guangzhou (HAIC, Zoledronic acid)

Recruiting
  • Hepatocellular Carcinoma
  • HAIC
  • Zoledronic acid
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
May 10, 2023

/or PD-1 Inhibitors for Unresectable Intrahepatic

Completed
  • Intrahepatic Cholangiocarcinoma
  • hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 7, 2022

Colorectal Liver Metastases Trial in Beijing (Tislelizumab, Regorafenib, HAIC)

Recruiting
  • Colorectal Liver Metastases
  • Beijing, Beijing, China
  • +1 more
May 25, 2023

Hepatocellular Carcinoma Trial (HAIC(FOLFOX), Oxaliplatin, Leucovorin)

Not yet recruiting
  • Hepatocellular Carcinoma
  • HAIC(FOLFOX)
  • +5 more
  • (no location specified)
Aug 16, 2022

Hepatocellular Carcinoma Trial in Wuhan (Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemo, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Nocardia rubra cell wall skeleton
  • +3 more
  • Wuhan, Hubei, China
    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College,
Sep 5, 2022

Hepatocellular Carcinoma, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemo Trial in Chongqing (Esketamine,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • Chongqing, Chongqing, China
    The Second Affiliated Hospital, Chongqing Medical University
Jun 9, 2022

Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)

Not yet recruiting
  • Potentially Resectable Hepatocellular Carcinoma
  • (no location specified)
Nov 16, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Intrahepatic Cholangiocarcinoma Trial in GuangZhou (HAIC Combined with Tislelizumab and Apatinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • HAIC Combined with Tislelizumab and Apatinib
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 4, 2022

Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Nov 16, 2022

Hepatocellular Carcinoma Trial in Wuhan (HAIC, Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Nov 8, 2022

Intrahepatic Cholangiocarcinoma Trial in Guangzhou (HAIC Combined with Tislelizumab and Apatinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • HAIC Combined with Tislelizumab and Apatinib
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
May 28, 2022

Hepatocellular Carcinoma, Chemo Effect, Chemotherapeutic Toxicity Trial in Guangzhou (Oxaliplatin,calcium folinic acid,

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
  • +4 more
  • Guangzhou, Guangdong, China
    SUN Yat-sen University Cancer Center
Sep 11, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Hepatic arterial infusion chemo, Lenvatinib, Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Nanfang Hospital of Southern Medical University
Aug 5, 2021

Unresectable Hepatocellular Carcinoma Trial in Guangzhou (dTACE-HAIC, HAIC, dTACE-HAIC protocol)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • dTACE-HAIC
  • +3 more
  • Guangzhou, Guangdong, China
    the Second Affiliated Hospital of Guangzhou Medical University
Feb 22, 2022

C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou (Hepatic Arterial Infusion combined with Apatinib

Recruiting
  • C-staged Hepatocellular Carcinoma in BCLC Classification
  • Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 3, 2022